share_log

艾美疫苗：截至二零二四年二月二十九日止之股份發行人的證券變動月報表

AIM VACCINE: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 1 03:38
Summary by Moomoo AI
艾美疫苗股份有限公司於2024年2月29日向香港交易及結算所有限公司提交了新的證券變動月報表。報告顯示，截至2024年2月底，公司的H股和內資股股份數量未發生變動，分別維持在492,173,711股和718,888,888股，股份面值均為1人民幣。此外，根據公司2020年11月30日採納並於2022年2月16日修訂的首次公開發售前僱員股份激勵計劃，本月底可行使的股份期權數目為10,870,000股，但本月內未有新股份因行使期權而發行。公司確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
艾美疫苗股份有限公司於2024年2月29日向香港交易及結算所有限公司提交了新的證券變動月報表。報告顯示，截至2024年2月底，公司的H股和內資股股份數量未發生變動，分別維持在492,173,711股和718,888,888股，股份面值均為1人民幣。此外，根據公司2020年11月30日採納並於2022年2月16日修訂的首次公開發售前僱員股份激勵計劃，本月底可行使的股份期權數目為10,870,000股，但本月內未有新股份因行使期權而發行。公司確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
EMERY VACCINES CO., LTD. FILED A NEW MONTHLY STATEMENT OF SECURITIES CHANGES WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON FEBRUARY 29, 2024. The report shows that as of the end of February 2024, the number of H shares and equity shares of the company remained unchanged at 492,173,711 shares and 718,888,888 shares, respectively, with a face value of 1 RMB. In addition, under the Company's initial public offering pre-sale employee share incentive plan adopted on November 30, 2020 and amended on February 16, 2022, the number of share options available at the end of the month was 10,870,000 shares, but no new shares were issued during the month as a result of the exercise of the options. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
EMERY VACCINES CO., LTD. FILED A NEW MONTHLY STATEMENT OF SECURITIES CHANGES WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON FEBRUARY 29, 2024. The report shows that as of the end of February 2024, the number of H shares and equity shares of the company remained unchanged at 492,173,711 shares and 718,888,888 shares, respectively, with a face value of 1 RMB. In addition, under the Company's initial public offering pre-sale employee share incentive plan adopted on November 30, 2020 and amended on February 16, 2022, the number of share options available at the end of the month was 10,870,000 shares, but no new shares were issued during the month as a result of the exercise of the options. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more